Lucoridalines

Summary

Lucoridalines (CHEMBL5314637) is a phase-3 clinical-stage unknown; indicated across 2 conditions including dyspepsia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314637
Name	Lucoridalines
Type	Unknown
Max phase	3

Also known as: DA-9701, DA9701, Lucoridalines, Motilitone, LUCORIDALINES

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dyspepsia	2	MONDO:0002268	EFO:0008533

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE4	3
Not specified	3
PHASE3	1
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01719575	PHASE4	COMPLETED	Clinical Trial of Motilitone on Gastric Motor Function in Healthy Volunteers
NCT02775591	PHASE4	COMPLETED	Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms
NCT03022201	PHASE4	COMPLETED	Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson’s Disease
NCT02533349	PHASE3	UNKNOWN	Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease
NCT01669772	PHASE1/PHASE2	COMPLETED	Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Volunteers
NCT02365701	PHASE2	COMPLETED	Study of Motilitone to Treat Functional Dyspepsia
NCT02091635	Not specified	COMPLETED	Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method
NCT02151708	Not specified	UNKNOWN	Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method
NCT04350346	Not specified	UNKNOWN	The Comparative Analysis Between Motilitone and Gasmotin for the Symptom Relief in Gallstone Patients With Functional Dyspepsia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).